SAR422459

Gene therapy / editing

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
NCT01736592 · Sanofi
2012-12-14 – 2033-08-29 · Stargardt's Disease
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01367444 · Sanofi
2011-06-08 – 2019-08-16 · Stargardt's Disease
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SAR422459 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2033 (1)
August 2033 (1)
Phase 2Stargardt's DiseaseActive not recruiting
Est. primary completion 2033-08-29 · NCT01736592 · CT.gov ↗
What to watch

See the full readout calendar ↗